ABSTRACT

Background/Aim: Over the past two decades, several advances have been made in the management of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Yttrium-90 ($^{90}Y$) radioembolization has recently been made a treatment option for patients with HCC and PVTT. However, there is still a need to systematically evaluate the outcomes of $^{90}Y$ radioembolization for HCC and PVTT. We aimed to assess the safety and effectiveness of $^{90}Y$ radioembolization for HCC and PVTT. We performed a systematic review of clinical trials, clinical studies, and abstracts from conferences that qualified for analysis.

Materials and Methods: PubMed, EMBASE, Cochrane Database of Systematic Review, CINAHL, and the “gray” literature (Google Scholar) were searched for all reports (1991-2016) related to $^{90}Y$ radioembolization for HCC and PVTT. Results: A total of 14 clinical studies and three abstracts from conferences including 722 patients qualified for the analysis. The median length of follow-up was 7.2 months; the median time to progression was 5.6 months, and median disease control rate was 74.3%. Radiological response data were reported in five studies, and the median reported value of patients with complete response, partial response, stable disease, and progressive disease were 3.2%, 16.5%, 31.3%, and 28%, respectively. The median survival was 9.7 months for all patients, including the median overall survival (OS) were 12.1, 6.1 months of Child-Pugh class A and B patients, and the median OS were 6.1, 13.4 months of main and branch PVTT patients, respectively. The common toxicities were fatigue, nausea/vomiting, abdominal pain, mostly not requiring medical intervention needed no medication intervention.

Conclusions: $^{90}Y$ radioembolization is a safe and effective treatment for HCC and PVTT.

Key Words: Hepatocellular carcinoma, portal vein tumor thrombosis, radioembolization, toxicity, yttrium-90

Received: 31.10.2015, Accepted: 16.02.2016

How to cite this article: Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol 2016;22:353-9.
However, the optimal treatment for patients with HCC and PVTT remains largely controversial.\(^7\) Yttrium-90 (\(^{90}\)Y) radioembolization is a locoregional liver-directed therapy that involves transcatheter delivery of particles embedded with the radioisotope \(^{90}\)Y. In addition to obliteration of the arterial blood supply, the \(^{90}\)Y results in a 50–150 Gy dose of radiation to the tumor tissue, which results in tumor necrosis, including HCC and PVTT.\(^{13}\) It was reported that \(^{90}\)Y radioembolization is a safe and effective treatment for patients with HCC and PVTT.\(^6\) However, there is still a need to systematically evaluate the outcomes of this treatment modality.

The purpose of this study was to comprehensively review the safety and effectiveness of \(^{90}\)Y radioembolization for HCC and PVTT.

MATERIALS AND METHODS

Search strategy
PubMed, EMBASE, Cochrane Database of Systematic Review, CINAHL and the “gray” literature (Google Scholar) were searched from January 1, 1991 (the first commercial availability of the \(^{90}\)Y products) to January 25, 2016, for the full text describing \(^{90}\)Y in the treatment of HCC and PVTT (keywords: (Liver cancer or liver tumor or primary liver cancer or hepatocellular carcinoma); (portal vein tumor thrombosis or portal vein thrombosis); and (yttrium-90 or \(^{90}\)Y or TheraSphere or SIR-Spheres) and English language). We retrieved potentially relevant articles and reviewed their reference lists to find studies that our search strategy may have missed. Clinical trials, clinical studies, and abstracts from conferences that qualified for analysis were included in this review.

The primary objective of this study was to determine the overall survival (OS), and the secondary objectives were to identify the radiological response and clinical toxicity.

Inclusion criteria
The inclusion criteria were (1) clinical trials, clinical studies, or abstracts from conferences; (2) describing \(^{90}\)Y in the treatment of PVTT; (3) at least include the primary objective: OS. Exclusion criteria were as follows: (1) Review articles, animal studies, laboratory investigations, case reports, and case series; (2) any duplicated clinical studies. All the clinical trials, clinical studies, and abstracts from conferences were reviewed for qualification according to our study criteria.

Data extraction
A standardized data extraction database was created by tabulating the following information: First author, year of publication, prospective or retrospective design, quality criteria, number of patients, patient characteristics, assessment criteria (European Association for the Study of the Liver [EASL]; Response Evaluation Criteria in Solid Tumors [RECIST]; World Health Organization [WHO]), time to progression (TTP), disease control rate, radiological response, OS, and clinical toxicity. Two members of the research team conducted the literature search independently to verify data accuracy and completeness, with a third one resolving any discrepancy. Studies were classified into three levels of evidence as follows: Level I, randomized controlled trials (RCTs); level II, non-RCTs or well-designed cohort studies; and level III, observational studies, as described by the U.S. Preventive Services Task Force.

Definitions
OS was calculated in months for all subjects from the date of radioembolization treatment to the date of death or last follow-up. Disease control rate was defined as the percentage of patients who have achieved complete response (CR), partial response (PR), and stable disease (SD) to \(^{90}\)Y radioembolization.\(^{14}\)

RESULTS
The initial search yielded 225 English reports from January 1, 1991, to January 25, 2016. An additional search using Google Scholar found no additional relevant articles. Of the 225 reports, a total of 208 reports were excluded due to unqualified studies (n = 182), review articles (n = 21), and duplicated clinical studies (n = 5) [Figure 1]. Ultimately, a total of 17 reports, including 14 studies (five prospective and nine retrospective) and three abstracts from conferences were included in this study (Kokabi N, et al.;\(^{15}\) Mazzaferro V, et al.;\(^{16}\) Memon K, et al.;\(^{17}\) Woodall CE, et al.).
et al.\textsuperscript{[18]} Kulkik LM, et al.;\textsuperscript{[19]} Salem R, et al.;\textsuperscript{[20]} Garin E, et al.;\textsuperscript{[21]} Sangro B, et al.;\textsuperscript{[22]} Inarrairaegi M, et al.;\textsuperscript{[23]} Salem R, et al.;\textsuperscript{[24]} Tsai AL, et al.;\textsuperscript{[25]} Hilgard P, et al.;\textsuperscript{[26]} Akinwande O, et al.;\textsuperscript{[27]} Lee V1, et al.;\textsuperscript{[28]} Biederman DM, et al.;\textsuperscript{[29]} Kim YH, et al.;\textsuperscript{[30]} El Fouly A, et al.\textsuperscript{[31]} The quality of evidence was as follows: level II, n = 6, and level III, n = 11.

Table 1 summarizes the patient demographic characteristics of the included reports. A total of 722 cases were included in the final analysis. The median value of the percentage of male patients was 80.5% (range 70%–94.2%) with a median age of 64 years (range 56–67 years). The median percentage of the reported main PVTT was 42.1% (range 0%–100%), and the extrahepatic metastases present in a median of 12% cases (range 0%–31.9%). The median percentage of Child–Pugh class A, B, C were 67% (range 20%–92.7%), 33% (range 7.3%–62%), and 0 (0%–27%), respectively. The median value of the radioactivity delivered was 2.6 GBq (range 1.4–3.1 GBq). Of the 722 cases, glass microspheres were used in 540 cases, resin microspheres were used in 160 cases, and the other 22 cases were unspecified.

Table 2 summarizes the effectiveness of $^{90}$Y treatment of the included studies. The median length of follow-up was 7.2 months (range 6–36 months), the median TTP was 5.6 months (range 4.9–9 months), and the median disease control rate was 74.3% (range 16.7%–94%). Radiological response data were reported in five studies; the median reported value of patients with CR, PR, SD, and progressive disease were 3.2% (range 0%–12.2%), 16.5% (range 5%–73.2%), 31.3% (range 5%–64%), and 28% (range 0%–80%), respectively. OS results were reported in all studies, with the median survival being 9.7 months (range 3–23.7 months).

The Child–Pugh class A (n = 70) and B (n = 85) patients were reported in four studies (only two studies identified the total patients number), with median OS being 12.1 months (7.4–23.7 months) of Child–Pugh class A patients, and 6.1 months (5.6–7 months) of Child–Pugh class B patients [Table 2]. The main PVTT (n = 70) and branch PVTT (n = 100) patients were reported in three studies, with median OS being 6.1 months (4.5–12 months) of main PVTT patients, and 13.4 months (6.5–21.5 months) of branch PVTT patients [Table 2].

Table 3 presents a thorough overview of the toxicity associated with $^{90}$Y radioembolization. Although toxicities were not available for most of the included studies, the common toxicities were fatigue (range 2.9%–67%), abdominal pain (range 2.9%–57%), and nausea/vomiting (range 5.7%–28%).

**DISCUSSION**

This review demonstrated the median disease control rate as 74.3%, and median survival as 9.7 months following $^{90}$Y radioembolization for HCC and PVTT patients. The median OS were 12.1 and 6.1 months of Child–Pugh class A and B patients, respectively, and the median OS were 6.1 and 13.4 months of main and branch PVTT patients, respectively.

$^{90}$Y radioembolization treatment, a form of intraarterial brachytherapy, is a technique in which glass or resin particles...
are labeled with $^{90}$Y. The radioisotope $^{90}$Y is a pure $\beta$-emitter with no primary gamma radiation. HCC and PVTT are fed mainly by hepatic arterial system rather than portal venous blood. Therefore, the dominant arterial flow of malignant tissue allows the delivery of high doses of radiation to tumors while keeping the exposure of the healthy liver at minimum with selective $^{90}$Y microsphere distribution. It was reported that $^{90}$Y internal radiation therapy can provide tumor doses as high as 50–150 Gy, in contrast to traditional whole liver external beam radiation where the radiation dose has been limited to 30 Gy to prevent adjacent organ injury.\cite{12,33} To date, the published reports documented in this sample demonstrate that $^{90}$Y treatment can be used safely in patients with portal circulation compromised at the level of the first-order portal branches.\cite{12,17,34} Also, Tsai et al.\cite{10} reported that $^{90}$Y treatment is tolerated in patients with HCC and major PVTT, and the median OS (7 months) is promising.

Most of the studied patients had end-stage disease, reflected by the high proportion of patients with Child–Pugh class B or C and main PVTT. The median disease control rate in the review of studies was 74.3%, with a median TTP of 5.6 months, and median survival of 9.7 months. It demonstrates that $^{90}$Y radioembolization is an effective treatment for HCC and PVTT. $^{90}$Y may also lead to tumor downstaging, which might allow for subsequent surgical resection or radiofrequency ablation.

From this study, the median OS of patients in Child–Pugh class A was longer than patients in Child–Pugh class B (12.1

| Table 2: Summary of the outcomes of the included studies |
|---------------------------------------------------------|
| References     | No. of evaluable patients | Assessment criteria | Median FU (months) | TTP (months) | Disease control rate (%) | Response rates CR/PR/SD/PD | Overall survival (months) |
|----------------|---------------------------|---------------------|-------------------|-------------|-------------------------|---------------------------|--------------------------|
| Kokabi N.      | 30                        | mRECIST             | 17.4              | 9           | N/A                     | N/A                       | 13 (4.4-22)              |
| Mazzaferro V.   | 35                        | RECIST              | 36                | 7           | 74.3%                   | N/A                       | 13 (9-17)                |
| Woodall CE.    | 15                        | N/A                 | N/A               | N/A         | N/A                     | 3.2                       |                          |
| Salem R.       | 15                        | N/A                 | 7.2               | N/A         | N/A                     | N/A                       | 16.5                     |
| Memon K.       | 35 (CP A cases)           | WHO                 | N/A               | 5.6 (3.5-7.5)| 86%                     | 0/49/37/14                | 13.8 (9-18.8)           |
|                | 28 (CP B cases)           | WHO                 | N/A               | 4.9 (2.2-6.3)| 89%                     | 0/25/64/11                | 6.5 (5-7.5)             |
| Kulik LM.      | 12 (main PVTT)            | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 4.5                      |
|                | 25 (branch PVTT)          | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 10.2                     |
| Salem R.       | 35 (CP A, PVTT mixed)     | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 10.4                     |
|                | 16 (main PVTT)            | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 7.7                      |
|                | 19 (branch PVTT)          | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 16.6                     |
|                | 57 (CP B, PVTT mixed)     | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 5.6                      |
|                | 30 (main PVTT)            | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 4.5                      |
|                | 27 (branch PVTT)          | WHO                 | N/A               | N/A         | N/A                     | N/A                       | 6.5                      |
| Garin E.       | 41 (total)                | EASL                | N/A               | 85%         | 12.2/73.2/14.6/0        | 18                        |
|                | 12 (main PVTT)            | EASL                | N/A               | N/A         | N/A                     | N/A                       | 12                       |
|                | 29 (branch PVTT)          | EASL                | N/A               | N/A         | N/A                     | N/A                       | 21.5                     |
|                | N/A (CP A, PVTT mixed)    | N/A                 | N/A               | N/A         | N/A                     | N/A                       | 23.7                     |
|                | N/A (CP B, PVTT mixed)    | N/A                 | N/A               | N/A         | N/A                     | N/A                       | 7                       |
| Sangro B.      | 76                        | N/A                 | N/A               | N/A         | N/A                     | N/A                       | 10                       |
| Inarrairaegui M. | 24             | RECIST              | 8                 | N/A         | 94%                     | N/A                       | 10 (6.6-13.3)           |
| Tsai AL.       | 22                        | RECIST              | 9                 | N/A         | 58%                     | 0/8/50/42                 | 7 (4.5-6.7)             |
| Hilgard P.     | 33                        | RECIST              | N/A               | N/A         | N/A                     | N/A                       | 10                       |
| Akinwande O.   | 20                        | mRECIST             | 22                | N/A         | 20%                     | 10/5/50/80                | 3                        |
| Lee VH.        | 12                        | N/A                 | N/A               | 16.7%       | N/A                     | N/A                       | 4.4                      |
| Biederman DM.  | 97 (total)                | mRECIST             | N/A               | N/A         | N/A                     | N/A                       | 9.3                      |
|                | 72 (glass)               | mRECIST             | N/A               | N/A         | N/A                     | N/A                       | 15 (8.6-19.5)            |
|                | 25 (resin)               | mRECIST             | N/A               | N/A         | N/A                     | N/A                       | 4.1 (2.7-6.6)            |
| Kim YH.        | 47                        | mRECIST             | 6                 | N/A         | 49.9%                   | 6.4/6.6/25.5/51.1         | 10.3 (5.7-14.8)         |
| El Fouly A.    | 90 (total)                | N/A                 | N/A               | N/A         | 4.9                     | N/A                       | 6.1 (5.4-6.8)            |
|                | N/A (CP A, PVTT mixed)    | N/A                 | N/A               | N/A         | N/A                     | N/A                       | 7.4 (5.1-9.8)            |
|                | N/A (CP B, PVTT mixed)    | N/A                 | N/A               | N/A         | N/A                     | N/A                       | 3.6 (2.7-4.4)            |

CP: Child-Pugh class, PVTT: Portal vein tumor thrombosis, EASL: European association for the study of the liver, RECIST: Response evaluation criteria in solid tumors, mRECIST: Modified response evaluation criteria in solid tumors, WHO: World health organization, FU: Follow-up, N/A: Not available, TTP: Time to progression, CR: Complete response, PR: Partial response, SD: Stable disease, PD: Progressive disease.
vs 6.1 months); and the median OS of patients in branch PVTT was longer than that in main PVTT patients (13.4 vs 6.1 months). It shows that tumor progression was slower in patients with Child–Pugh class A and branch PVTT than patients with Child–Pugh class B and main PVTT.

Although embolization with 90Y does result in permanent vascular blockade with glass or resin particles, the smaller caliber of the particles (20–30 μm glass, 20–60 μm resin) impart the theoretical advantage of a lesser degree of macroscopic arterial occlusion. It was reported that the 90Y treatment exerts less of an ischemic effect compared with TACE (threefold lower incidence of postembolization syndrome). [35]

Overall, 90Y treatment is a well-tolerated procedure, especially when compared with TACE. The most frequently encountered toxicities are symptoms of the post-radioembolization syndrome, including fatigue, abdominal pain, nausea/vomiting, and fever. Although the incidence of symptoms of post-radioembolization syndrome was not reported in most of the included studies, the common toxicities were abdominal pain, nausea/vomiting, and fatigue. Fortunately, postembolization syndrome can be managed with medication and the symptoms generally subside within a week post-radioembolization.

**Study limitation**

This study was limited by the small number and quality of included studies, as only 14 studies and three abstracts were included and the overall evidence was level II or III by the U.S. Preventive Services Task Force, and all the included studies were not specifically focused on and lacked details related to the etiological factors (especially hepatitis B- and hepatitis C-related HCC). Also, the number of patients and the observation time was short in the included studies, all of which may bias the results. Furthermore, only four studies mentioned the OS of different Child–Pugh class (A/B) and three studies mentioned the OS of different PVTT location (main/branch), which may also bias the results. Lastly, we cannot prove which 90Y product (glass/resin) is better due to the small studied sample of only 160 cases that used resin microsphere.

**CONCLUSIONS**

90Y radioembolization is a safe and effective treatment for HCC and PVTT. However, this study lacks adequate power to draw definitive conclusions based on the presented data. A larger cohort might allow more meaningful conclusions and more robust survival data.

**Financial support and sponsorship**

This study was supported by High-level Medical Talents Training Project of Changzhou (NO. 2016CZBJ009 and NO. 2016CZLJ007). Social Development Fund of Jiangsu Science and Technology (NO. BE2016658). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12:7561-7.

| Table 3: Summary the toxicity of patients in the included studies |
| --- |
| References | No. of evaluable patients | Total | Fatigue | Abdominal pain | Nausea/vomiting | Fever | Ascites | Elevated bilirubin |
| Kokabi N. | 30 | N/A | 67% | 57% | N/A | N/A | N/A | 27% |
| Mazzaferro V. | 35 | 17.2% | 2.9% | 2.9% | 5.7% | 2.8% | 2.9% | N/A |
| Memon K. | 63 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Woodall CE. | 15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Kulik LM. | N/A | 50% | 22% | N/A | 28% | N/A | N/A | N/A |
| Salem R. | 15 | 20% | N/A | N/A | N/A | N/A | N/A | 20% |
| Garin E. | 41 | 6% | N/A | N/A | N/A | N/A | N/A | N/A |
| Sangro B. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inarrairaegui M. | 25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Salem R. | 92 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tsai AL. | 22 | 38% | N/A | 38% | N/A | N/A | N/A | N/A |
| Hilgard P. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Akinwande O. | 20 | 31% | N/A | N/A | N/A | N/A | N/A | N/A |
| Lee VH. | 12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Biederman DM. | 97 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Kim YH. | 47 | 19.1% | 17% | N/A | N/A | N/A | N/A | N/A |
| El Fouly A. | 90 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

N/A: Not available
Radioembolization with yttrium-90 glass microspheres in patients with hepatic tumors. Med Phys 2003;30:199-203.

A two-arm, randomised clinical trial. J Cancer Res Clin Oncol 2014;140:211-9.

Pracht M, Edeline J, Lenoir L, Latournerie M, Membah H, Audrain O, et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: Preliminary results. Int J Hepatol 2013;2013:827649.

Bienert M, McCook B, Carr BL, Geller DA, Sheetz M, Tutor C, et al. 90Y microsphere treatment of unresectable liver metastases: Changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 2005;32:778-87.

Sznol M. Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: Useful endpoint or hype? Curr Opin Investig Drugs 2010;11:1340-1.

Kokabi N, Camacho JC, Xing M, El-Rayes BF, Spivey JR, Knechtle SJ, et al. Radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Cancer 2015;121:2164-74.

Mazzaferrro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 2013;57:18-26.

Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. J Hepatol 2013;58:73-80.

Woodall CE, Scoggins CR, Ellis SF, Tatum CM, Hali MJ, Ravindra KV, et al. Selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 2009;208:375-82.

Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: From palliation to cure. Cancer 2006;106:1653-63.

Lu J, Dong J, Ji L, Xiao LX, Ling CQ, Zhou J. Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombus. J Cancer Res Clin Oncol 2011;137:139-49.

Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002;359:1734-9.

Opin Investig Drugs 2010;11:1340-1.
et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. Nucl Med 2000;41:1673-81.

34. Kokabi N, Camacho JC, Xing M, Qiu D, Kitajima H, Mittal PK, et al. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Abdom Imaging 2014;39:969-78.

35. Goin JE, Dancey JE, Roberts CA, Sickles CJ, Leung DA, Soulen MC. Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: Transcatheter chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med 2004;3:49-56.